Although most of them are developed to treat various types of inflammatory diseases, e.g., CCX9664, a small molecule antagonist of CCR6, is being studied in rheumatoid arthritis [138], they are also potential candidates for the treatment of cancer [138] (Figure 3). The gene discussed is CCR6; the disease is cancer.